Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211
- Category: Small Molecules
- Published on Friday, 06 December 2019 12:43
- Hits: 794
THE WOODLANDS, TX, USA I December 05, 2019 ILexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1 (AAK1), in development for the treatment of neuropathic pain.
"We are pleased that the initial clinical data for LX9211 in the multiple ascending dose study supports continued advancement of the drug," said Praveen Tyle, Ph.D., executive vice president of research and development at Lexicon. "LX9211 was well tolerated with dose proportional pharmacokinetics, similar to what was seen in the single ascending dose study. We expect to initiate a proof-of-concept study for LX9211 early next year.”
The randomized, double-blind, placebo-controlled, multiple ascending dose Phase 1 study was performed to evaluate the safety, tolerability and pharmacokinetics of orally administered LX9211 in healthy volunteers. The study was comprised of five cohorts over a wide loading dose range of 25 mg to 200 mg followed by a maintenance dose for 14 days. LX9211 demonstrated a favorable safety and pharmacokinetics profile supportive of once-daily dosing and exhibited dose proportional pharmacokinetics. The most common adverse events were headache and dizziness, and there were no drug-related serious adverse events.
LX9211 is a potent, orally delivered, selective small molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain. Lexicon has exclusive research, development and commercialization rights to LX9211 and additional compounds acting through AAK1.
About Lexicon Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism, oncology and neuropathic pain. For additional information, please visit www.lexpharma.com.
SOURCE: Lexicon Pharmaceuticals